NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/08/2026 10:58
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization11,228 mln
Float13.79 mln
Earnings Date08/11/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
1.29
Highly suspicious
1-Year Forecast
679
Exceptional upside
Relative Strength
19
/ 100
Significantly lagging
Debt / Equity
0.64
Moderate leverage
ROE
-48.68
Deeply negative
Business Description
Madrigal Pharmaceuticals is a US-based drug developer dedicated to treating a serious liver disease caused by metabolic disorders. Its flagship product, Rezdiffra, works by targeting specific receptors in the liver to address the condition. Founded in 2016 and based in West Conshohocken, Pennsylvania, the company remains focused on expanding treatment options for patients with this underserved disease.
